Drug profile · INN
bosutinib monohydrate
BOSULIF
bosutinib monohydrate (BOSULIF) is a bcr/abl fusion protein. Route of administration: film coated. Current US regulatory status: approved.
Drug details — bosutinib monohydrate
- US status
- approved
- Class
- —
- Route
- FILM COATED
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
bosutinib monohydrate (BOSULIF) is a bcr/abl fusion protein. Route of administration: film coated. Current US regulatory status: approved.
Key facts
Mechanism of action
Bcr/Abl fusion protein
Primary target: Bcr/Abl fusion protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Related & competitor drugs
Frequently asked questions
What is bosutinib monohydrate?
bosutinib monohydrate (BOSULIF) is a bcr/abl fusion protein. Route of administration: film coated. Current US regulatory status: approved.
What is the brand name for bosutinib monohydrate?
BOSULIF is a marketed brand name for bosutinib monohydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bosutinib monohydrate?
bosutinib monohydrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.